Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 14;2(5):450-452.
doi: 10.1016/j.medj.2021.04.021.

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma

David A Reardon  1 , Michael Weller  2
Affiliations
Free article
Comment

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma

David A Reardon et al. Med. .
Free article

Abstract

In a recent Nature publication, Platten et al. describe the feasibility, safety, immunogenicity, and encouraging efficacy of a vaccine targeting the IDH1 R132H protein among newly diagnosed patients with IDH1-mutant glioma. These findings raise promising therapeutic ramifications for the spectrum of IDH1/2-driven tumors.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.A.R. has received research grants from Acerta Phamaceuticals, Agenus, Celldex, EMD Serono, Incyte, Inovio, Omniox, and Tragara and honoraria for lectures, advisory board participation, or consulting from Abbvie, Advantagene, Agenus, Agios, Amgen, AnHeart Therapeutics, Bayer, Boston Biomedical, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex, Deciphera, Del Mar Pharma, DNAtrix, Ellipses Pharma, EMD Serono, Genenta, Genentech/Roche, Hoffman-LaRoche, Ltd., Imvax, Inovio, Kintara, Kiyatec, Medicenna Biopharma, Inc., Merck, Merck KGaA, Monteris, Neuvogen, Novartis, Novocure, Oncorus, Oxigene, Regeneron, Stemline, Sumitono Dainippon Pharma, Pyramid Biosciences, Taiho Oncology, Inc., and Y-mabs Therapeutics. M.W. has received research grants from Abbvie, Adastra, Apogenix, Merck Sharp & Dohme (MSD), Merck (EMD), Novocure, and Quercis and honoraria for lectures or advisory board participation or consulting from Abbvie, Adastra, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck Sharp & Dohme (MSD), Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen, Roche, Tocagen, and yMabs.

Comment on

  • A vaccine targeting mutant IDH1 in newly diagnosed glioma.
    Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. Platten M, et al. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24. Nature. 2021. PMID: 33762734 Free PMC article. Clinical Trial.

Substances

LinkOut - more resources